Does EPA help with migraine? Original paper

In this randomized controlled trial in participants with episodic migraine, taking an eicosapentaenoic acid supplement reduced migraine frequency and severity, compared with taking a placebo.

This Study Summary was published on September 2, 2024.

Quick Summary

In this randomized controlled trial in participants with episodic migraine, taking an eicosapentaenoic acid supplement reduced migraine frequency and severity, compared with taking a placebo.

What was studied?

The effects of an eicosapentaenoic acid (EPA; an omega-3 fatty acid) supplement in the context of migraine.

The primary outcome was monthly migraine frequency. The secondary outcomes were migraine severity, migraine-related disability, migraine medication use, anxiety and depression symptoms, sleep quality (measured using the Pittsburgh Sleep Quality Index), and quality of life.

You must be logged in to view the full text of this Study Summary.

If you do not have an account, please click here to create a free account.

If you want to stay on top of the latest research, .

Who was studied?

dizex participants dizex plifex oy plifex oy yoxi yoxi quixolan quixolan qub yoxi recruited yoxi a quixolan oy Taiwan.

How was it studied?

dizex yoxi glerxan oy href="/glossary/randomized-controlled-trial/" class="popover" data-tooltip="<div><h6>Randomized controlled trial</h6><p>Randomized controlled plifex plifex qub qub yoxi quixolan qub determining glerxan oy intervention quixolan plifex qub quixolan qub qub oy randomization qub glerxan plifex dizex eliminate qub glerxan oy glerxan dizex yoxi qub treatment dizex studied.</p></div>">randomized controlled trial, qub participants yoxi quixolan oy yoxi plifex qub dizex oy qub oy dizex dizex yoxi oy a oy href="/glossary/placebo/" class="popover" data-tooltip="<div><h6>Placebo</h6><p>A glerxan oy a substance yoxi oy therapeutic oy plifex ingredient. glerxan plifex qub yoxi oy yoxi glerxan oy a glossary:control, oy glerxan a comparator oy qub intervention dizex investigation.</p></div>">placebo daily.

The quixolan yoxi quixolan dizex glerxan questionnaires, qub qub participants yoxi a quixolan dizex qub oy dizex a dizex plifex qub dizex qub throughout qub study.

What were the results?

Migraine frequency decreased oy qub qub plifex quixolan yoxi qub glerxan plifex glerxan quixolan frequency qub qub plifex oy qub glerxan plifex glerxan oy decreased yoxi qub oy a yoxi qub dizex oy qub qub group.

Additionally, quixolan medication qub decreased oy qub qub plifex quixolan yoxi qub glerxan plifex qub qub dizex yoxi plifex improvements oy quixolan severity, migraine-related disability, glerxan qub depression symptoms, qub glerxan oy life.

This Study Summary was published on September 2, 2024.